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1. INTRODUCTION 
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1.1. Chronic kidney disease 
 Wide spectrum of pathophysiological processes that are associated with abnormal kidney 
function are known as chronic kidney disease (CKD). A cornerstone feature of CKD is a decline 
in glomerular filtration rate (GFR). There is a strong link between the glomerular filtration rate 
and the amount of albuminuria with the risk of CKD progression. GFR levels are used to determine 
the stage of the kidney disease, as presented in Figure 1 (1). 
 
Figure 1. Relationship between the GFR and the risk for progression, morbidity and mortality of 
CKD 
Source: The National Kidney Foundation 2019 [Internet]. Available online: 
https://www.kidney.org/atoz/content/gfr 
3 
 
End stage renal disease, like the name suggests, is the final stage of CKD where all the 
electrolytes, toxins and fluid that are excreted in a healthy kidney accumulate in the patient. This 
leads to morbidity and death if left untreated (2). End stage renal disease imposes sever limitations 
to the quality of life of afflicted patents. Every aspect of life is impaired and restricted. End stage 
renal disease is a prevalent and important health issue around the world. Furthermore, current 
prediction is that by the year 2020 there will be an increase of almost 60% of patients suffering 
from end stage renal disease when compared to 2005  (3, 4). 
The signs and symptoms that occur as a result of end stage renal disease are known 
collectively as uremic syndrome. Urea and creatinine are used to estimate kidney function, 
however, their accumulation in the body alone does not cause uremic syndrome. A vast number of 
different toxins that build up in the kidney during end stage renal disease are all implicated in 
uremic syndrome (5). Uremic syndrome is not limited to the accumulation of toxins but also, 
multiple organ dysfunction and gut microbiota dysbalance. Uremic syndrome can thus be 
considered a disturbance of inter-organ and inter-organism (host–microbiota) communication (5). 
The consequences of uremic syndrome include anemias, malnutrition due to dysfunctional 
metabolism of proteins, fats and carbohydrates. As a result of decreased excretion, reduced 
degradation and aberrant regulation plasma levels of various hormones including glucagon, 
insulin, steroid hormones; vitamin D and prolactin are abnormal (2). 
Importantly, end stage renal disease has an association with a rise in systemic 
inflammation. Levels of acute phase reactants such as C-reactive protein are raised. Negative acute 
phase reactants such as fetuin and albumin are decreased. This chronic inflammation is a catalyst 
in the malnutrition-inflammation-atherosclerosis cycle, which adds fuel to the flames and 
accelerates comorbidities associated with end stage renal disease. To summarize, uremic syndrome 
is due to losses in the kidneys excretory function, hormonal and metabolic function and progressive 
systemic inflammation (2, 5). Complications of end stage renal disease are not only limited to 
direct consequences of uremic syndrome but also an increased risk of associated complications 
such as aortic stenosis (6). Furthermore, patients with CKD have dramatically increased risk of 
cardiovascular events (7). 
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1.1.1. Etiology and epidemiology 
 The global rise in the number of patients with CKD is threatening to reach epidemic 
proportions, and only a minor number of countries have a robust economies capable to meet 
challenges presented (8). This growing burden of CKD is mainly driven by population ageing (9). 
Population data estimates that approximately 6% of the adult population in the United States has 
CKD between stages 1 and 2. In addition to this, 4.5% of the United States population is estimated 
to have stages 3 and 4 CKD (2). There is a large amount of patients who suffer from early stages 
of kidney disease (CKD stages 1-3), and yet are unaware of their condition and do not have a 
diagnosis (10).  
Data that was collected from the European Renal Association − European Dialysis and 
Transplant Association indicates that the overall prevalence of CKD is expected to increase, this 
is due to the following reasons, improved dialysis and transplant survival, increase in the relative 
prevalence of transplants and overall improvements in survival and treatment. As a whole, the 
European rate has risen from 124 patients per million in 2010 to 133 patients per million in 2014 
(11). On the other hand the incidence of renal replacement therapy for diabetic nephropathy in 
Europe has stabilized at approximately ∼32 ppm , this is in part due to improved prophylactic 
treatments for CKD (12). Furthermore, in the general population, a healthy 60-year-old individual 
can expect to live an additional 20 more years, however the life expectancy of a 60-year-old 
hemodialysis patient is only 4 or 5 years (11). 
The ratio of incidence to prevalence is high, this reflects a high mortality rate particularly 
in older patients. In the past, the country with the highest incidence for end stage kidney disease 
was Mexico followed by the United States, Taiwan and Japan. Prevalence was highest in Taiwan, 
Japan and U.S. The rankings reflect the universal health care provided for patients which keeps 
them alive. The country with the lowest prevalence reported was the Philippines (12). 
The five most common causes of CKD are diabetic nephropathy, glomerulonephritis, 
hypertension-associated CKD, autosomal dominant polycystic kidney disease and other cystic and 
tubulointerstitial nephropathy. Together, these five causes account for approximately 90% of all 
cases of CKD. Of the aforementioned causes, the most common cause in the United States and 
Europe is diabetic nephropathy, a complication of diabetes mellitus type 2. Furthermore, diabetic 
nephropathy is the leading cause of renal failure in developed countries (2, 13). Certain areas in 
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the world are still burdened with higher rates of diabetic kidney disease, whereas other parts of the 
world are experiencing a decrease in the prevalence and mortality. Screening is proposed as 
valuable tool in mitigating the rising problem of diabetic nephropathy in regions of high-risk (12). 
Further, annual monitoring of urinary albumin-to-creatinine ratio, estimated GFR, and blood 
pressure is recommended in diagnosed diabetes patients (14). Among diabetes patients, a higher 
mean glycemic exposure (HbA1c) was found to be the strongest modifiable risk factor associated 
with kidney disease development (15). 
Hypertension is often found in patients with newly diagnosed CKD and augmented 
cardiovascular disease is a frequent complication of renal diseases. With no evidence for primary 
renal parenchymal disease hypertension becomes the most likely cause (16). There are two 
categories these patients fall under. Patients with subclinical primary glomerulopathy such as 
focal, segmental or glomerular sclerosis, are one category i.e. the kidney is the primary cause of 
the pathology. The second group of patients are those that have systemic vascular disease which 
in turn affects the kidney. These vascular pathologies often involve large and small vessels and 
involve the heart and brain too. The second category of patients tend to be elderly. It should be 
stated that while increased survival of the elderly is a major factor in the increased incidence of 
CKD, most elderly patients in the early stages of CKD succumb to complications of the heart or 
brain before they progress into end stage kidney disease (2). 
Further, data collected from the European Renal Association − European Dialysis  is the  
large difference between European countries in the incidence of renal replacement therapy, ranging 
from 23 patients per million in the Ukraine compared to the highest value of 237 patients per 
million in Portugal. (17). 
 
1.1.2. Pathophysiology of chronic kidney failure 
As a result of kidney failure, numerous disorders develop including disrupted electrolytes, acid 
base misbalance, fluid overload, a drop-in hematopoiesis of red blood cells and more. End stage 
kidney disease is an important cause of premature death of patients (18). 
Stress to the blood vessels of the kidney glomerulus leads to the accumulation and 
activation of inflammatory cells which in turn activate and cause the dysfunction of mesangial 
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cells. Under the influence of various inflammatory cytokines (of note transforming growth factor 
β1 - TGFβ) mesangial cells regress into mesangioblasts. These mesangioblasts produce an excess 
of extracellular matrix resulting in a mesangial expansion. This is an early sign of 
glomerulosclerosis (8, 19). 
Decreased TGFβ signaling activity has been proven in several animal studies to have 
beneficial effects on renal outcomes. On the other hand, because of its pleiotropic nature, complete 
inhibition of the TGFβ signaling pathway would likely lead to harmful side effects. Thus, an 
improved understanding of this pathway, and the modulating molecules, is necessary for 
development of practical real world therapeutic strategies in the treatment of CKD (20). 
 Another pathophysiological mechanism of kidney damage is the stretching of podocytes 
leaving areas of denuded glomerular basement membrane which in turn leads to the formation of 
Bowman’s capsule adhesions. Moreover, disorders of podocyte architecture results in the 
retraction of foot processes and proteinuria and both appear to be shared consequences in the 
development of acquired glomerular disease. (21). 
 The aforementioned pathophysiological basis of kidney damage is presented in Figure 2. 
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Figure 2. Stages of glomerulosclerosis 
Source: Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet. 
2005;365(9456):331-40. 
 There are two main pathophysiological mechanisms in CKD. The first is based on the primary 
etiology that initially caused the CKD. This could be developmental, caused by immune complex 
deposits, glomerular nephritis or toxin exposure (2). The most common primary causes of end 
stage renal disease, that initiate the first pathophysiological mechanism, are diabetes mellitus and 
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hypertension. These conditions are associated with increased cardiac morbidity and mortality as 
well (22). The second mechanism is a consequence of the first one. The remaining undamaged 
nephrons begin to hypertrophy and filter a larger amount of fluid. This compensatory action 
actually leads to further decline in kidney function (8). 
Initially GFR is maintained as short term adaptations allow normal kidney function, despite 
a decrease in the number of nephrons. However, this increased pressure and flow begins to change 
the architecture of the glomeruli. Further changes that happen include abnormal podocyte function. 
An increase in the activity of renin-angiotensin system appears to contribute to the compensatory 
hyperfiltration and also to the consequential hypertrophy and sclerosis of the remaining nephrons. 
This is why reduced renal mass, due to the pathology, can over many years lead to a steady 
decrease in the function of renal parenchyma (2). End stage, stage 5 CKD, renal disease is the 
dramatic end to all kidney functions and results in the development of uremic syndrome (23). It 
should be acknowledged that kidney transplantation is ultimate treatment with the greatest survival 
rate, quality of life and cost effectiveness for patients with end stage renal disease (24).  
 
1.2. Dialysis and extracorporeal therapies 
1.2.1. Hemodialysis 
Hemodialysis (HD) is a medical procedure where blood is moved out of the patient into 
extracorporeal circulation and then back the vasculature. It is the most common method of 
treatment for end stage renal disease. HD was a necessary procedure to sustain the lives of an 
estimated 2.6 million end stage patients around the globe in 2010 with this figure expected to 
double by 2030. Without HD, death from uremic syndrome can be expected in a few weeks (25, 
26). The goal of HD is to replace the kidneys excretory function. Unwanted solutes including urea, 
potassium, phosphorus etc. are diffused into the dialysate. The dialysate circuit allows a 
hydrostatic pressure gradient to diffuse excess water from the blood thus maintain normovolemia. 
Replacement of kidney hormone function is a secondary goal (2). 
During extracorporeal transit the blood is filtered. This is performed with an 
electrochemical concentration gradient using osmotic principles. Blood is separated from a 
solution called dialysate which contains necessary electrolytes to restore balance in the kidney 
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failure patient. The advent of hemodialysis has made the rapidly terminal diagnosis of kidney 
failure and subsequent uremic syndrome a thing of the past (2). A concentration gradient between 
the blood and dialysate is maintained with a counter current flow i.e. the dialysate flows in the 
opposite direction to the blood. The dialysate allows potassium, urea, phosphates and waste 
products to diffuse out of the blood, the concentration of sodium and chloride is the same in the 
dialysate as the blood thus preventing a change in blood concentration of these electrolytes. 
Bicarbonate is added in higher concentrations to the dialysate solution to restore normal blood pH 
(27). 
The temperature of dialysate is kept between 35° and 37° C. At a constant temperature of 
37° C the dialysate will cause the patients core temperature to paradoxically rise. It is not 
understood why, but one theory is that as a result of the bodies perceived loss of blood from the 
vessels and into the extracorporeal HD system, there is compensatory vasoconstriction, which in 
turn decreases any heat loss (28-30).. As the temperature increases, a reflex dilation occurs in the 
peripheral blood vessels causing decreased peripheral vascular resistance and a drop in the 
intradialytic pressure (hypotension).  
Of the vascular access routes available for initiating HD the arteriovenous (AV) fistula is 
the most preferred. This type of fistula is made by connecting an artery with an adjacent vein. 
Different types of fistulas are presented in Figure 3. Things to consider when deciding lumen size 
are patient size, comorbidities like diabetes and obesity. Preoperative ultrasonographic imaging of 
the veins called vein mapping is useful in outlying the specific patient anatomy and may increase 
the rate of successfully establishing an AV fistula when distal fistulas fail or distal vessels are 
inadequate the alternative becomes the upper arm veins (31-33). 
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Figure 3. Varieties of upper arm fistulas 
Source: Pereira B, Sayegh M, Blake P. Chronic kidney disease, dialysis, and transplantation. 2nd 
ed. Philadelphia: Saunders; 2005. 
 
The cephalic and basilica can both be used to create an AV fistula. The basilica however, 
requires the additional procedure up and out from its anatomical position deep within the fascia. 
The brachiobasilic fistula can be made in several stages, firstly transposioned and then secondly 
anastomosed. Procedure can be advantages in adults and children. The basilic vein can also 
successfully be transposioned to the forearm. Meta-analysis of over 12,000 patients found that 
over time the failure rate for fistulas could be increasing, and this leads to concerns whether fistulas 
as a first step in HD therapy could be an overdone and unnecessary approach (33, 34). Further, in 
patients who exhaust all options for arteriovenous access in upper extremities an arteriovenous 
thigh graft is a potential vascular access (35). 
It has been acknowledged that fistula creation is necessary in order to avoid the use of 
central venous catheters. However, it is still unclear which timing of fistula creation is preferable 
in order to minimize catheter use. In study by Clarke et al. patients’ outcomes of predialysis (fistula 
attempt prior to initiation of the dialysis) and postinitiation (fistula attempt after starting dialysis) 
strategies were compared. The study involved 1091 patients, and the results showed that 
predialysis fistula attempts are associated with higher chance of catheter free use. However, 
catheter use was still common for both strategies of fistula creation (36).  
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Polytertrafluroethaline (ePTFE) is now the most widely used material for AV vascular 
access, and it secured its place as the most popular material by being easy to place and not taking 
a lot of time to do so. The recognized advantage of an AV graft is that it does not require an 
adequate vein in the forearm, but still provides an access for placement. One major advantage of 
these grafts is its low rate of thrombosis early on; however, this does not last and the patency rate 
of 12 months is only approximately 50 %. Graft material is at high risk of infection, infected grafts 
can be salvaged if the infected section is resected and the artificial material is replaced (39). 
The AV graft initiates a biological response inside the lumen and in the distal part of the 
native vein. A number of different immune responses occur, amongst these is cellular growth 
inside and distal to the lumen itself. The consequent hyperplasia results in a high incidence of 
stenosis which is the number one cause of graft failure (38). Most stenosis develops at the venous 
anastomosis. Stents are often used to reduce the incidence of stenosis in grafts, the use of drug 
eluting stents, and its effectiveness is at this point undetermined. However, drug eluting graft 
material has shown promise in animal model (39) The future of grafts is a totally biological system, 
artificial materials will be just the skeleton on which autologous fibroblasts will be grown, after 
this endothelial cells will be seeded inside the lumen. This technology would provide grafts that 
are less likely to be affected by infections and thrombosis (40). 
 
1.2.1.1. Complications of hemodialysis 
Hypotensive events may occur in 15-30 but up to even 50% of all HD patients. Risk factors 
for this complication, among others, are female gender, older age and comprised heart function 
(41). Another complication, dialysis disequilibrium syndrome, is characterized by altered mental 
status, generalized seizures and coma. The occurrence of this syndrome has declined partly due to 
the earlier initiation of maintenance HD therapy. A less severe form of the syndrome includes 
symptoms of nausea and vomiting, headaches, fatigue and restlessness, and this form is still 
prevalent among HD patients (42). 
It has been stated that available guidelines have discouraged the use of central venous 
catheters. Furthermore, one of the reasons that this is the case is because this route has been 
associated with higher incidence of complications. For instance, bacteremia occurs more frequent 
in this patient group, and it is their leading cause of hospitalization. However, some patients have 
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inadequate vessels for fistula creation, and they are only accessible to catheters. Therefore, the 
risks of catheters should be communicated to patients in order to prevent future complications (43). 
An important symptom that reduces the health-related quality of life in HD patients are 
common muscle cramps. They can occur both during HD and in intradialytic periods, and are fairly 
painful. The cramps during HD could be due to exaggerated fluid removal, hypotension or perhaps 
shifts in electrolytes, but the cause is not precisely identified at this point. Another theory is that 
the accumulation of uremic solutes could account for intradialytic cramping. At this point in time 
there is no universal preventative measures that would reduce the duration or the frequency of 
patients cramps during HD. However, in some cases, changes in the frequency or duration of 
dialysis could be helpful. A number of different substances may have the ability to reverse 
intradialytic muscle cramps, and these include most commonly saline bolus followed by 
hypertonic infusions or dextrose solution. A meta-analysis results have suggested that L-carnitine 
administration could be helpful. Furthermore, vitamin E has showed variable efficacy in 
decreasing muscle cramps as well (44,45). 
The most severe complications that can occur in HD patients are arrhythmias, myocardial 
stunning and death as their consequence. Concomitant heart disease predisposes patients to 
arrhythmias and possibly cardiac arrest during HD. Furthermore, HD causes a shift in solutes from 
intracellular to extracellular fluid, especially when the rate of removal is fast, and this is another 
predisposing factor to increased risk of arrhythmias. Change in the level of serum potassium is 
another important factor in arrhythmia occurrence, as are the changes in magnesium, calcium and 
pH serum values.  Patients who use medicine that affect potassium, for instance digoxin, have even 
more complicated potassium control as this drug further affects electrolyte disbalance. For high 
risk patients, a computer programmed potassium removal (potassium modeling) could be 
beneficial. Moreover, the most feared occurrence in outpatient HD is a cardiac arrest. Despite 
external defibrillators, that are simple to use, the survival rate after one year for those patients is 
only approximately 15%. Furthermore, patients with internal defibrillators have a 2.7 times higher 
chance of death when on HD compared to the general population (46-49). 
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1.3. Quality of life in hemodialysis patients 
Quality of life is an ambiguous term that can refer to the experience an individual has of 
the objective living conditions the individuals find themselves in. It is thus a very subjective term. 
People who have disabilities can describe their quality of life as excellent and people who are 
healthy can describe their quality of life as poor. Generally, quality of life is the degree of which 
an individual is in good health, comfort and able to enjoy events in their own life. In medicine, 
quality of life is a multidimensional term which encompasses wealth, social, physical and 
emotional wellbeing of an individual. The majority of medical procedures are based on objective 
findings. However, it should be acknowledged that the often neglected aspect, the subjective 
experience of patient, can have major influence on the disease course (50). 
For HD to be effective, patients require the procedure approximately 3 times a week. This 
means that their whole lives need to revolve around their schedule, which imposes restrictions on 
every aspect of their living. This specificity of HD, among other factors, is what influences 
patients’ quality of life the most. Therefore, observing patient-reported outcomes, to capture HD 
influences on health-related quality of life, has been recognized as an important factor for the 
improvement of health and individual care in CKD patients. Further, several questionnaires were 
developed in order to evaluate quality of life impairment in CKD patients. Short form health survey 
appeared to be the most used questionnaire in the studies of quality of life in end stage renal disease 
patients. A more specific questionnaire adopted to CKD patients is Kidney Disease Quality of Life 
Questionnaire-Short Form. A limitation of the quality of life questionnaires is the absence of 
assessment of family satisfaction, despite the fact that this is a crucial aspect of patients’ lives (51-
53). 
Assessing the quality of life in HD patients not only has value in measuring the 
effectiveness of the therapy, but it also can be predictive of the outcome. Health-related quality of 
life has been found to have a significant predictive value on the survival and hospitalization of 
patients with chronic kidney disease. Moreover, quality of life places a role in deciding when a 
patient begins HD therapy. Needless to say, the most important factor that is taken into 
consideration when making the decision to initiate HD is the stage of the kidney disease and 
clinical picture. However, another important factor to consider is the patient’s life style and the 
role they play in family and community. A patient who is very involved in the community may 
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forego HD initiation (disease permitting) for a while longer when compared to a retired patient at 
a similar stage of disease. This patient specific approach to decision making can be supplemented 
with information about patients’ quality of life (51, 53, 54). 
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2. OBJECTIVES 
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The aims of this study are: 
1. To evaluate quality of life in male and female hemodialysis patients 
2. To determine malnutrition-inflammation score in male and female hemodialysis patients 
3. To analyze connection between malnutrition-inflammation score and quality of life in 
hemodialysis patients. 
 
Hypothesis: 
1. There will be no differences in quality of life between male and female hemodialysis 
patients.  
2. There will be no differences in malnutrition-inflammation score between male and female 
hemodialysis patients.  
3. There will be a negative correlation between malnutrition-inflammation score and the 
quality of life in hemodialysis patients. 
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3. SUBJECTS AND METHODS 
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3.1. Study design 
This cross-sectional study was conducted at Department of Nephrology, University 
Hospital of Split and Department of Pathophysiology, University of Split School of Medicine. 
Study was performed from August 2018 till December 2018.  
 
3.2. Ethics approval and consent to participate 
The included participants were informed about the procedures and the aim of this study, 
and their written informed consent was obtained. This study was approved by the Ethics 
Committee of the University Hospital of Split. Every procedure performed during this study was 
in accordance with the ethical standards of the institutional or national research committee and 
with 1964 Helsinki declaration, or its later amendments. 
 
3.3. Study participants 
Fifty hemodialysis (HD) patients were included in the presented study (26 male and 24 
female patients). Inclusion criteria were outpatients who had been undergoing HD treatment for at 
least 6 months, who were 18 years or older and who signed the approved consent form. Patients 
with acute infections or an anticipated life expectancy of less than 6 months (e.g. due to a 
metastatic malignancy) were excluded. 
A validated questionnaire Medical Outcomes Study Short Form-36 (SF-36) was used in 
the present study to assess participants’ health-related quality of life. SF-36 is a multifunctional, 
non-disease specific, 36-question health survey that evaluates 8 domains of health providing an 
overall assessment of health-related quality of life. All questions are scored on a scale from 0 to 
100, with 100 representing the highest level of functioning possible. Health aspects that are being 
valued are physical functioning, physical role limitations, bodily pain, general health perception, 
social functioning, emotional role limitations, emotional well-being and vitality. The scores from 
those questions that address each specific area of functional health status are then averaged 
together, for a final score within each of the 8 dimensions measured (55). 
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Body weight assessment and anthropometric measurements were performed according to 
the conventional medical standards within 5 to 20 minutes after termination of the treatment. 
Detailed medical history was obtained from anamnestic data, medical records and self-report. 
After regular clinical evaluation, all patients were asked to complete SF-36 questionnaire.  
Furthermore, for each participant a malnutrition-inflammation score (MIS) was calculated.  
The MIS has four sections (nutritional history, physical examination, body mass index, and 
laboratory values) and 10 components. Each component has four levels of severity, from 0 
(normal) to 3 (severely abnormal). The sum of all 10 MIS components can range from 0 (normal) 
to 30 (severely malnourished). A higher score reflects a more severe degree of malnutrition and 
inflammation in dialysis patients (56). 
 
3.4. Data analysis 
 Statistical software MedCalc ver. 11.5.1.0 for Windows (MedCalc Software, Ostend, 
Belgium) was used for data analysis. Data were expressed as means ± standard deviation for 
continuous variables and as whole numbers and percentage for categorical variables. Kolmogorov-
Smirnov test has been used for normality of data distribution.  
Chi-square test or student t-test were used to compare baseline population characteristics 
for men and women. Student t-test was used for comparison of different domains of SF-36 between 
men and women. Pearson’s correlation coefficient was used for assessment of correlation between 
SF-36 domains and other variables and correlation between MIS and baseline characteristics of 
study participants. The statistical significance was defined as P<0.05. 
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4. RESULTS 
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 Baseline characteristics measured in hemodialysis patients are presented in Table 1. 
Differences between men and women were observed in body weight, both before and after the 
dialysis, but not in BMI value. Furthermore, female patients had a longer duration of chronic 
kidney disease, when compared to male patients (27.6±19.9 vs. 16.1±16.2 years; P=0.031). 
Table 1. Baseline population characteristics 
Data presented as mean ± standard deviation or number (percentage) where appropriate 
*t-test for independent samples or chi-square test 
 
 For majority of the patients included in the present study the most common vascular access 
route for initiating HD was arterio-venous fistula (Figure 4).  
 
Parameter 
Men 
(N=26) 
Women 
(N=24) 
Total 
(N=50) 
P* 
Age (years) 69.4±12.7 68.0±12.5 68.7±12.7 0.684 
Body weight before dialysis (kg) 82.8±14.8 64.6±13.9 74.1±16.9 <0.001 
Body weight after dialysis (kg) 80.6±14.8 62.5±13.7 71.9±16.8 <0.001 
Body height (cm) 179.6±7.9 166.1±6.5 173.1±9.9 <0.001 
Waist circumference (cm) 102.8±10.1 92.1±13.8 97.7±13.1 0.002 
Hip circumference (cm) 107.2±10.8 101.2±11.6 104.3±11.4 0.065 
BMI (kg/m2) 25.6±4.6 22.8±6.0 24.3±5.4 0.070 
Duration of chronic kidney disease (years) 16.1±16.2 27.6±19.9 21.6±18.9 0.031 
Duration of dialysis treatment (years) 6.4±6.3 9.5±11.4 7.8±9.2 0.236 
Arterial hypertension (N, %) 14 (53.8) 9 (37.5) 27 (54.0) 0.251 
Smoking (N, %) 4 (15.4) 7 (29.2) 11 (22.0) 0.244 
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Figure 4. Distribution of patients according to venous approach to hemodialysis 
 
Patients self-assessment of health-related quality of life is presented in Table 2. Females 
had statistically significantly lower scores than males in the following domains: physical 
functioning (48.7±35.0 vs. 68.4±26.9; P=0.029), energy/vitality (70.4±20.1 vs. 84.6±12.0; 
P=0.004), emotional well-being (71.8±18.1 vs. 83.5±10.1; P=0.008), pain (75.5±36.8 vs. 
95.7±14.2; P=0.005) and general health perception (37.1±10.4 vs. 44.6±14.9; P=0.042). 
 
 
 
 
 
 
 
 
Table 2. SF-36 scores between males and females 
Arterio-venous fistula
52%Temporary central 
venous catheter
24%
Permanent central 
venous catheter
24%
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Data presented as mean ± standard deviation  
*t-test for independent samples 
 
 
Older age was associated with lower quality of life in 4 of the questionnaire domains: 
physical functioning (r= -0.334; P=0.017), role limitations both physical (r= -0.298; P=0.035) and 
emotional (r= -0.361; P=0.010) and social functioning (r= -0.309; P=0.029). Moreover, the 
duration of the disease only negatively influenced the domain of general health perception (r= -
0.283; P=0.047), The amount of time on dialysis negatively affected the domains of energy/vitality 
(r= -0.326; P=0.020) and emotional well-being (r= -0.282; P=0.047). 
 
 
 
Table 3. Correlation of age, duration of chronic kidney disease and duration of dialysis treatment 
score with SF-36 domains 
SF-36 dimensions 
Men 
(N=26) 
Women 
(N=24) 
Total  
(N=50) 
P* 
Physical functioning 68.4±26.9 48.7±35.0 59.0±32.3 0.029 
Role limitations physical 80.7±40.2 66.6±48.1 74.0±44.3 0.269 
Role limitations emotional 70.1±25.4 60.6±29.1 65.4±27.5 0.221 
Energy/vitality 84.6±12.0 70.4±20.1 77.8±17.7 0.004 
Emotional well-being 83.5±10.1 71.8±18.1 77.9±15.6 0.008 
Social functioning 78.3±34.0 61.4±37.9 70.2±36.5 0.104 
Pain 95.7±14.2 75.5±36.8 84.1±29.8 0.005 
General health perception 44.6±14.9 37.1±10.4 41.0±13.4 0.042 
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SF-36 domain 
Age          
(years) 
r*(P) 
Duration of 
CKD (years) 
r*(P) 
Duration of dialysis 
(years) 
r*(P) 
Physical functioning -0.334 (0.017) -0.082 (0.572) -0.214 (0.135) 
Role limitations physical -0.361 (0.010) -0.033 (0.817) -0.155 (0.281) 
Role limitations emotional -0.298 (0.035) -0.045 (0.756) -0.195 (0.174) 
Energy/vitality -0.080 (0.578) -0.205 (0.154) -0.326 (0.020) 
Emotional well-being -0.017 (0.907) -0.193 (0.178) -0.282 (0.047) 
Social functioning -0.309 (0.029) -0.129 (0.370) -0.197 (0.170) 
Pain 0.073 (0.616) -0.203 (0.157) -0.231 (0.107) 
General health perception -0.252 (0.077) -0.283 (0.047) -0.263 (0.065) 
CKD – chronic kidney disease 
* Pearson’s correlation coefficient 
 
There was a statistically significant difference in the MIS score between males and females 
with females having a higher score than male patients (7.45±4.31 vs. 5.28±3.18; P=0.048) (Figure 
5). 
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Figure 5. Differences in MIS between men and women 
 
 Correlation between MIS and baseline characteristics and SF-36 domains are presented in 
Tables 4 and 5. There was a statistically significant negative correlation between MIS and all 
anthropomorphic parameters (Table 4). Moreover, there was statistically significant negative 
correlation between MIS and all domains of SF-36 questionnaire (Table 5). 
 
Table 4. Correlations between baseline characteristics and MIS score 
Parameter 
MIS 
r* P 
BMI (kg/m2) -0.420 0.002 
Waist circumference (cm) -0.331 0.018 
Hip circumference (cm) -0.344 0.014  
Age (years) -0.005 0.972  
Duration of chronic kidney disease (years) 0.032 0.822  
Duration of dialysis treatment (years) 0.182 0.205 
* Pearson’s correlation coefficient 
0
2
4
6
8
10
12
14
M
IS
Men Women
P*=0.048
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Table 5. Correlations between SF-36 domains and MIS 
Parametar 
MIS  
r* P 
Physical functioning -0.582 <0.001 
Role limitations physical -0.318 0.024 
Role limitations emotional -0.318 0.024  
Energy/vitality -0.527 <0.001  
Emotional well-being -0.565 <0.001  
Social functioning -0.480 <0.001 
Pain -0.465 <0.001 
General health perception -0.476 <0.001 
* Pearson’s correlation coefficient  
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 In the present study female patients had lower score in all domains of SF-36 questionnaire 
and it can be stated that they reported lower health related quality of life when compared to men. 
Our results were in concordance with a 2016 study that also found a negative association between 
female sex and quality of life (57). Future studies should investigate association of female gender 
with these specific domains in order to provide patient centered care to female patients. This is 
however contrary to some previous findings. In study by He et al. the men patients experienced 
more negative emotions when compared to women patients. However, both patient group reported 
relatively poor quality of sleep and quality of life (58). Another study had several negative 
predictive factors identified and among these was male gender. However, this particular study was 
conducted in Saudi Arabia where males play a dominant role in society and for whom illness of 
any kind could have large changes to the life they have grown accustomed to (59).  In contrast to 
our study and the aforementioned Saudi study, a 2015 Greek study found no statistically significant 
difference between the quality of life in males and females (60).  
It should be acknowledged that males and females included in this study did not differ in 
duration of dialysis treatment, prevalence of arterial hypertension or any other baseline 
characteristic, except duration of CKD. However, the duration of the disease did not show a strong 
correlation with health related quality of life in presented study. Therefore, it can be assumed that 
poorer quality of life reported in women is not a direct consequence of longer duration of the 
disease in this patient group.  
The difference between females and males was also observed in malnutrition evaluation. 
Higher MIS observed in female patients reflects a more severe degree of malnutrition and 
inflammation, compared to male dialysis patient. In recently published research by Rodrigues et 
al. MIS showed the strongest association with hospitalization and mortality risk when compared 
to other nutritional markers of HD patients (61). Moreover, increased malnutrition could be the 
cause of low life satisfaction in patients (62). Therefore, the more severe degree of malnutrition in 
women could have influenced their self-perceived lower quality of life as MIS was highly 
correlated with HD patients’ quality of life in the presented study. 
Study by Gencer et al. reported positive correlation between the duration of dialysis and 
MIS (62). However, our study did not have the same finding. An explanation of this difference in 
results of two studies with similar sample sizes could be the fact that published study involved 
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younger patients. Future studies are needed to give a definite conclusion of relationship between 
duration of dialysis and MIS.  
Additionally, duration of the dialysis was correlated with domains energy and emotional 
well-being of SF-36 questionnaire in our study. Previous studies have also found a correlation 
between decreasing quality of life and amount of time spent on HD. Even though this can be a 
logical conclusion of many years’ patients have been living with a life restricting therapy. 
However, some studies contradict these findings and indicate no relationship between quality of 
life and time on HD. This discrepancy could be due to a difference in provided quality of care at 
different hospitals (59,63). 
 Health related quality of life of the study participants was strongly correlated with their age 
in several domains. Similar findings were observed in some previous studies. Elderly experience 
functional decline within the first 6 months after initiating HD. This risk is even higher in older 
and frail patients. Loss in functional status in this patients group is driven by decline in 
instrumental activities of their daily life (64). 
 Additionally, a small number of patients included in this study reported that they were 
smokers. However, it has been stated that smoking imposes higher cardiovascular risks for CKD 
patients on HD, as it is associated with higher levels of serum phosphorus. Furthermore, in study 
by Li et al., which involved 22 230 HD patients, risks for death and hospitalization were elevated 
for smokers group of HD patients. Moreover, the highest risks were amongst younger HD patients 
and those patients with diagnose of diabetes. Interestingly, second-hand smoke was not associated 
with risks. Clinicians should become aware of the risks for HD patients and help their patients with 
smoking cessation (65,66). 
 The main limitations of the presented study are small sample size and that it is a single 
center study. Moreover, the addition of control group of healthy participants would have added a 
value to the results of this study. Further, several other factors could have influenced patients’ 
quality of life, and were not included in the present study. For instance, impact of the depression 
and level of education on quality of life in HD patients was observed in previous studies (67,68). 
Even with the presented limitations our results are consisted with findings of previous studies. 
Furthermore, this study should rise awareness of health care professionals of quality of life 
measurements and MIS, since both could influence HD patients’ outcomes. 
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6. CONCLUSION 
31 
 
1. Female patients on hemodialysis reported lower health related quality of life when 
compared to males.  
2. Female patients had higher MIS in comparison to male patients.  
3. There was statistically significant negative correlation between MIS and all domains of the 
SF-36 questionnaire.  
4. The amount of time on dialysis negatively affected the domains of energy/vitality and 
emotional well-being.  
5. Duration of the chronic kidney disease only negatively influenced the domain of general 
health perception. 
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Objectives: Living on hemodialysis is a challenge to many patients, impacting various aspects of 
their lives and ultimately influencing their quality of life. The aim of this was to determine the 
differences in quality of life between male and female patients on hemodialysis and to evaluate the 
relationship between quality of life and malnutrition-inflammation score. 
Patients and methods: This study included 50 patients in total, 26 males and 24 females. To 
evaluate health related quality of life the Short Form-36 questionnaire was utilized. This is a 
multifunctional, non-disease specific 36 question health survey in 8 different domains. In addition 
to this, the malnutrition-inflammation score (MIS) which included four sections (nutritional 
history, physical examination, body mass index, and laboratory values) was determined.  
Results: Females had statistically significantly lower scores than males in the following domains: 
physical functioning (48.7±35.0 vs. 68.4±26.9; P=0.029), energy/vitality (70.4±20.1 vs. 
84.6±12.0; P=0.004), emotional well-being (71.8±18.1 vs. 83.5±10.1; P=0.008), pain (75.5±36.8 
vs. 95.7±14.2; P=0.005) and general health perception (37.1±10.4 vs. 44.6±14.9; P=0.042). Older 
age was associated with lower quality of life in 4 of the questionnaire domains: physical 
functioning (r= -0.334; P=0.017), role limitations both physical (r= -0.298; P=0.035) and 
emotional (r= -0.361; P=0.010) and social functioning (r= -0.309; P=0.029). Moreover, the 
duration of the chronic kidney disease only negatively influenced the domain of general health 
perception (r= -0.283; P=0.047). The amount of time on dialysis negatively affected the domains 
of energy/vitality (r= -0.326; P=0.020) and emotional well-being (r= -0.282; P=0.047). 
Additionally, there was statistically significant negative correlation between MIS and all domains 
of SF-36 questionnaire. 
Conclusion: We can conclude that female patients on dialysis had lower health related quality of 
life when compared to men. Furthermore, quality of life inversely correlated with malnutrition-
inflammation status. 
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Naslov: Malnutricijsko-inflamacijski zbir i kvaliteta života u pacijenata na hemodijalizi. 
Ciljevi: Život na hemodijalizi izazov je za mnoge pacijente, koji utječe na različite aspekte 
njihovog života i naposljetku utječe na njihovu kvalitetu života. Cilj ovog istraživanja bio je 
utvrditi razlike u kvaliteti života između muškaraca i žena koje su na hemodijalizi i utvrditi vezu 
između kvalitete života i zbira pothranjenosti. 
 Pacijenti i metode: Ispitivanje je obuhvatilo ukupno 50 pacijenata, 26 muškaraca i 24 žene. Za 
procjenu zdravstvene kvalitete života korišten je Upitnih zdravstvenog stanja SF-36. Ovo je 
multifunkcionalni, bolest nespecifični, zdravstveni upitnik s 36 pitanja u 8 različitih domena. Uz 
to, izračunat je i malnutricijsko-inflamacijski zbir (MIS) koji je uključivao četiri dijela (povijest 
prehrane, fizički pregled, indeks tjelesne mase i laboratorijske vrijednosti).  
Rezultati: Žene su imale statistički značajno niži zbir od muškaraca u sljedećim domenama: 
fizičko funkcioniranje (48,7±35,0 nasuprot 68,4±26,9; P=0,029), energija/vitalnost (70,4±20,1 
nasuprot 84,6±12,0; P=0,004), emocionalno blagostanje (71,8±18,1 nasuprot 83,5±10,1; 
P=0,008), bol (75,5±36,8 nasuprot 95,7±14,2; P=0,005) i percepcija općeg zdravlja (37,1±10,4 
nasuprot 44,6±14,9; P=0,042). Starija dob bila je povezana s nižom kvalitetom života u 4 područja 
upitnika: fizičko funkcioniranje (r=-0,334; P=0,017), ograničenja zbog fizičkih (r=-0,361; 
P=0,010) i emocionalnih poteškoća (r=-0,361; P=0,010) i socijalno funkcioniranje (r=-0,309; P= 
0,029). Nadalje, trajanje kronične bubrežne bolesti samo je negativno utjecalo na domenu 
percepcije općeg zdravlja (r=-0.283; P=0.047). Vrijeme provedeno na dijalizi negativno je utjecalo 
na domenu energija/vitalnost (r= -0,326; P=0,020) i emocionalno blagostanje (r=-0,282; P=0,047). 
Pronađena je statistički značajna negativna korelacija između MIS zbira i svih domena SF-36 
upitnika. 
Zaključak: Žene su imale nižu procjenu kvalitete života u usporedbi s muškarcima. Nadalje, 
kvaliteta života je negativno korelirala sa zbirom pothranjenosti.  
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